Back Pain News and Research

Latest Back Pain News and Research

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Bacterin anticipates 134% increase in revenue for second-quarter 2011

Bacterin International Holdings, Inc., a leader in the development of revolutionary bone graft material and anti-infective coatings for medical applications, expects to report its seventh consecutive quarter of record revenue growth.

18 Jul 2011

Bacterin forays into medical devices with acquisition of Robinson MedSurg

Bacterin International Holdings, Inc., a leader in the development of revolutionary bone graft material and anti-infective coatings for medical applications, has acquired the assets of Robinson MedSurg LLC (RMS), a medical device distribution company focused primarily on maxillofacial and craniofacial surgery devices.

18 Jul 2011

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

St. Jude Medical, Inc., a global medical device company, today announced the U.S. Food and Drug Administration (FDA) clearance and limited market release of the Epiducer lead delivery system for neurostimulation therapy.

13 Jul 2011

Tel Aviv University researcher finds link between back pain and genetics

A common complaint, back pain is one of the many side effects of aging. Over three quarters of the population experience it at some point, and until now, researchers have had little conclusive proof of the causes and mechanisms of the pain.

6 Jul 2011

Massage therapy more effective for patients with chronic low back pain

Massage therapy helps ease chronic low back pain and improve function, according to a randomized controlled trial that the Annals of Internal Medicine will publish in its July 5 issue.

5 Jul 2011

Chiropractors report high number of back-related injuries during summer moving period

Each year, chiropractors notice a recrudescence of patients that come for a consultation during the summer moving period. Not surprising when we know that many people, eager and tired, hasten to get everything done rapidly without worrying about their muscles and their back. That explains why herniated discs, lumbar pain and muscle soreness are so common during this time of year. How can we avoid this?

30 Jun 2011

100 million Americans suffer pain - many in silence

According to a report released by the Institute of Medicine Wednesday, nearly a third of Americans experience long-lasting pain and too often feel stigma rather than relief from a health care system poorly prepared to treat them. Chronic pain is costing the nation at least $558 billion a year in medical bills, sick days and lost productivity, the report found. That's more than the cost of heart disease, the top killer.

30 Jun 2011

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Genentech, a member of the Roche Group, announced today that, during a U.S. Food and Drug Administration (FDA) hearing, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated HER2-negative metastatic breast cancer.

30 Jun 2011

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Dendreon Corporation today announced that the U.S. Food and Drug Administration approved its Los Angeles cancer immunotherapy manufacturing facility, allowing the company to continue to increase the availability of PROVENGE across the U.S. to help meet the needs of patients with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer.

30 Jun 2011

Physical activity can positively affect cells in intervertebral discs

Physical exercise has a positive effect on the formation of cells in the intervertebral discs. This is shown by a study from the Sahlgrenska Academy, University of Gothenburg, presented at the annual meeting of the International Society for the Study of the Lumbar Spine (ISSLS), which is currently taking place in Gothenburg.

29 Jun 2011

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

Amgen today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand the indication for XGEVA (denosumab) to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases.

28 Jun 2011

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Baxter International Inc. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy (MMN), a severe, debilitating disorder requiring lifelong treatment.

From Baxter International Inc. 24 Jun 2011

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Sanofi-aventis announced today that Health Canada has granted market authorization for Jevtana injection in combination with prednisone for the treatment of patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing treatment regimen.

24 Jun 2011

Spinal manipulative therapy provides minor but significant benefits for patients with chronic low back pain

Spinal manipulative therapy (SMT) has significant but very small benefits for patients with chronic low back pain, according to a special review article in the June 1 issue of Spine.

23 Jun 2011

Loyola offers powerful new MRI machine without usual inconveniences

Loyola University Health System now offers a powerful new MRI machine that can scan a leg or an arm without many of the usual inconveniences.

23 Jun 2011

Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl (APIS), announced today that the Paul-Ehrlich-Institut, Germany's healthcare regulatory body for biological products, has authorized initiation of an open-label clinical trial to investigate eculizumab as a treatment for patients with Shiga-toxin producing E. coli hemolytic uremic syndrome, which has resulted from infections by Enterohemorrhagic Escherichia coli in an unusually wide outbreak in Germany that began in May.

20 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Back Pain News and Research

Latest Back Pain News and Research

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Bacterin anticipates 134% increase in revenue for second-quarter 2011

Bacterin forays into medical devices with acquisition of Robinson MedSurg

FDA clears St. Jude Medical's Epiducer lead delivery system for neurostimulation

Tel Aviv University researcher finds link between back pain and genetics

Massage therapy more effective for patients with chronic low back pain

Chiropractors report high number of back-related injuries during summer moving period

100 million Americans suffer pain - many in silence

FDA's ODAC recommends withdrawal of Avastin approval for metastatic breast cancer

Dendreon receives FDA approval for Los Angeles cancer immunotherapy manufacturing facility

Physical activity can positively affect cells in intervertebral discs

Amgen files sBLA for XGEVA with FDA to treat castrate-resistant prostate cancer

EMA CHMP issues positive opinion for Baxter's IVIG therapy for multifocal motor neuropathy

Health Canada grants market authorization for Sanofi-aventis Jevtana to treat prostate cancer

Spinal manipulative therapy provides minor but significant benefits for patients with chronic low back pain

Loyola offers powerful new MRI machine without usual inconveniences

Alexion begins eculizumab clinical trial in Shiga-toxin producing E. coli hemolytic uremic syndrome

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Back Pain News and Research

Latest Back Pain News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in